"Hemispherx Biopharma has hired Squire Patton Boggs as its global government relations firms to pursue distribution opportunities for its two Ebola drugs [Ampligen and Alferon N]. - Kevin McCauley, "Ebola Drug Developer Hires Squire Patton Boggs," in Odwyerpr.com, October 20, 2014. Here is that article.
Squire Patton Boggs, with offices in 21 countries, is now in the front lines of addressing the Ebola threat around the world. It will lobby officials in the U.S., Europe, and Africa about using the drugs.
The media have switched from fear-mongering about Ebola to decrying the lack of universal access to experimental and FDA-approved drugs. Hemispherx Biopharama's Ampligen is experimental and Alferon N is FDA-approved.
Both Hemispherx Biopharma and Squire Patton Boggs can potentially receive tremendous publicity. This will certainly be the situation if there are more cases of Ebola in the U.S. and Europe.
Congratulations to the new entity Squire Patton Boggs for acquiring this account.